Characteristics of adults with CAP requiring hospitalisation or managed in the community
| Pneumococcal group (n=59) | Non-pneumococcal group (n=127) | CAP cohort (n=186) | |
| Demographics | |||
| Age years | 79 (71 to 83) | 79 (73 to 85) | 79 (73 to 85) |
| Male | 42 (71.2) | 79 (62.2) | 121 (65.1) |
| Reporting | |||
| Hospital physicians | 38 (64.4) | 105 (82.7) | 143 (76.9) |
| GPs | 21 (35.6) | 22 (17.3) | 43 (23.1) |
| Any underlying comorbidity* | |||
| Chronic heart disease | 28 (47.5) | 70 (55.1) | 98 (52.7) |
| Chronic respiratory disease | 29 (49.2) | 52 (40.9) | 81 (43.6) |
| Diabetes | 14 (23.7) | 32 (25.2) | 46 (24.7) |
| Chronic kidney disease | 2 (3.4) | 9 (7.1) | 11 (5.9) |
| Chronic liver disease | 2 (3.4) | 3 (2.4) | 5 (2.6) |
| Malignancy | 0 | 4 (3.1) | 4 (2.1) |
| Asplenia | 1 (1.7) | 1 (0.8) | 2 (1.1) |
| Status regarding receipt of pneumococcal vaccination† | |||
| PCV13 | 5 (8.5) | 15 (11.8) | 20 (10.8) |
| PPSV23 given <5 years prior to study enrolment | 20 (33.9) | 40 (31.5) | 60 (32.3) |
| Outcomes‡ | |||
| 30-day mortality | 2 (3.4) | 2 (1.6) | 4 (2.2) |
| Recovery with sequelae | 5 (8.5) | 20 (15.7) | 25 (13.4) |
Data are number, median (IQR) or number (%).
*The groups were not mutually exclusive and therefore do not sum to 100%.
†For both vaccines, patients were considered to be vaccinated if they had received the vaccine at least 2 weeks before enrolment. Data were missing for four patients in the non-pneumococcal group. One patient had received a dose of PCV13 ≥1 year after receipt of a PPSV23 dose given <5 years prior to study enrolment.
‡Data were missing for 20 patients in the pneumococcal group and 40 patients in the non-pneumococcal group.
CAP, community-acquired pneumonia; GPs, general practitioners; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.